Immune globulin 10% - Octapharma

Drug Profile

Immune globulin 10% - Octapharma

Alternative Names: 10% high purity immunoglobulin; 10% IVIG; Intravenous immunoglobulin 10% - Octapharma; NewGam; octagam 10%; Panzyga

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Octapharma
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Immune thrombocytopenic purpura; Immunodeficiency disorders
  • Phase II/III Chronic inflammatory demyelinating polyradiculoneuropathy
  • Discontinued Alzheimer's disease

Most Recent Events

  • 30 Mar 2016 Octapharma plans the phase III ProDERM trial for Dermatomyositis in USA (IV) (NCT02728752)
  • 15 Mar 2016 Biomarkers information updated
  • 18 Dec 2015 Octapharma plans the phase III ProCid trial for Chronic inflammatory demyelinating polyradiculoneuropathy in USA (IV) (NCT02638207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top